Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?
MilliporeSigma, part of the German Merck group, has agreed to provide CDMO services for SaudiVax. The Merck offshoot will design a multi-modality manufacturing plant for the Saudi company, which is pursuing the development and manufacture of halal biotherapeutics and vaccines. Financial terms of the arrangement have not been disclosed.
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
